Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN   US75886F1075

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Regeneron: Sanofi Plans to Increase Stake to Over $500 Million of Stock

02/11/2013 | 10:44am US/Eastern
   By Melodie Warner 
 

Regeneron Pharmaceuticals Inc. (>> Regeneron Pharmaceuticals Inc) said Sanofi S.A. (SNY, SAN.FR) notified the biopharmaceutical company of its intent to boost its investment in the company and push its ownership of voting securities to more than $500 million.

Sanofi currently holds about 17% of Regeneron's shares outstanding, according to FactSet Research.

Regeneron said a December 2007 investor agreement bonds the French drug maker to certain standstill provisions, including an agreement not to acquire more than 30% of Regeneron's Class A stock and common stock outstanding.

Regeneron said these standstill provisions are in effect until the fifth anniversary of the expiration of a license and collaboration agreement between the companies.

Sanofi and Regeneron have worked together on experimental cancer drug Zaltrap, among other things.

Shares of Regeneron rose 5.6% to $175.13 in recent trading and have climbed 24% in the past three months.

Write to Melodie Warner at melodie.warner@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Regeneron Pharmaceuticals Inc
React to this article
Latest news on REGENERON PHARMACEUTICALS
1d ago REGENERON PHARMACEUTICALS : Assigned Patent
2d ago REGENERON PHARMACEUTICALS : Entry into a Material Definitive Agreement (form 8-K..
2d ago REGENERON PHARMACEUTICALS : Patent Issued for Methods of Treating Diabetes with ..
4d ago REGENERON PHARMACEUTICALS : Biotech Stocks in Motion - Amgen, Merrimack Pharma, ..
7d ago REGENERON PHARMACEUTICALS : Entry into a Material Definitive Agreement (form 8-K..
7d ago SANOFI : and Regeneron's atopic dermatitis drug receives FDA breakthrough therap..
11/20 Sanofi touts new drugs but diabetes outlook disappoints
11/20 REGENERON PHARMACEUTICALS : Assigned Patent
11/19 REGENERON PHARMACEUTICALS : and Sanofi Announce Positive Results from Phase 2b S..
11/19 REGENERON PHARMACEUTICALS : Patent Application Titled "Methods and Compositions ..
Advertisement
Chart
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF